How big is Phathom Pharmaceuticals, Inc.?

As of Jun 18, Phathom Pharmaceuticals, Inc. has a market capitalization of 733.05 million and reported net sales of 81.85 million with a net profit of -345.80 million over the latest four quarters. Shareholder's funds are -253.58 million, and total assets are 378.47 million.

As of Jun 18, Phathom Pharmaceuticals, Inc. has a market capitalization of 733.05 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 81.85 million, while the sum of net profit for the same period is -345.80 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at -253.58 million, and total assets amount to 378.47 million.

What does Phathom Pharmaceuticals, Inc. do?

Phathom Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on developing treatments for gastrointestinal diseases. As of March 2025, it reported net sales of $29 million and a net loss of $94 million, with a market cap of $733.05 million.

Overview: <BR>Phathom Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 29 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -94 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 733.05 Million (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.04 <BR>Return on Equity: 102.19% <BR>Price to Book: -2.17 <BR><BR>Contact Details: <BR>Address: 100 CAMPUS DRIVE, SUITE 102, FLORHAM PARK NJ: 07932 <BR>Tel: 1 302 6365400 <BR>Fax: 1 302 6365454 <BR>Website: https://www.phathompharma.com/

Should I buy, sell or hold Phathom Pharmaceuticals, Inc.?

Who are in the management team of Phathom Pharmaceuticals, Inc.?

As of March 2022, the management team of Phathom Pharmaceuticals, Inc. includes Dr. Tadataka Yamada (Independent Chairman), Ms. Terrie Curran (President and CEO), and Mr. David Socks (CFO). The Board also features independent directors such as Mr. Michael Cola and Ms. Heidi Kunz.

As of March 2022, the management team of Phathom Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Dr. Tadataka Yamada, who serves as the Independent Chairman of the Board.<BR>- Ms. Terrie Curran, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. David Socks, who is the Co-Founder, Chief Financial Officer, Treasurer, and a Director.<BR><BR>Additionally, the Board of Directors includes several independent directors: Mr. Michael Cola, Ms. Heidi Kunz, Mr. Asit Parikh, Mr. Mark Stenhouse, and Dr. James Topper.

Is Phathom Pharmaceuticals, Inc. overvalued or undervalued?

As of May 9, 2024, Phathom Pharmaceuticals, Inc. is considered risky and overvalued due to negative valuation ratios and a one-year return of -38.90%, despite a strong YTD return of 44.70% that outperformed the S&P 500.

As of 9 May 2024, the valuation grade for Phathom Pharmaceuticals, Inc. has moved from does not qualify to risky. The company appears to be overvalued given its negative valuation ratios, including a Price to Book Value of -1.84, an EV to EBIT of -3.40, and an EV to EBITDA of -3.41. In comparison to peers, Amneal Pharmaceuticals, Inc. has a P/E of 48.88, while NewAmsterdam Pharma Co. NV shows a P/E of -20.32, highlighting the significant disparity in valuation metrics within the industry.<BR><BR>Additionally, Phathom's recent stock performance shows a YTD return of 44.70%, which outperformed the S&P 500's return of 12.22% during the same period, but the one-year return of -38.90% starkly contrasts with the S&P 500's 17.14%. This suggests that while there may be short-term gains, the long-term outlook remains concerning, reinforcing the notion that the stock is overvalued.

Is Phathom Pharmaceuticals, Inc. technically bullish or bearish?

As of October 31, 2025, Phathom Pharmaceuticals, Inc. shows a bullish technical trend with strong weekly MACD and Bollinger Bands, despite a mildly bearish KST signal, and has returned 66.13% year-to-date, though it underperformed over the past year with a -26.16% return.

As of 31 October 2025, the technical trend for Phathom Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish, indicating positive momentum. Daily moving averages also support a bullish stance. However, the KST shows a mildly bearish signal on the weekly timeframe, which slightly tempers the overall bullish outlook. <BR><BR>In terms of performance, the stock has returned 66.13% year-to-date compared to the S&P 500's 16.30%, but it has underperformed over the past year with a return of -26.16% versus the S&P 500's 19.89%. Overall, the current technical stance is bullish with moderate strength.